Pfizer and Perlegen Form New Genetics Research Collaboration to Analyze Patient DNA Samples

12/28/2005 08:00 AM

Perlegen Sciences, Inc. announced today a four-year research collaboration with Pfizer Inc for whole genome and replication studies that may identify genes associated with major diseases and predic...

 

Pfizer Invests $50 Million in Perlegen Sciences; Takes 12% Stake in Company That Seeks to Genetically Define Disease and Improve Understanding of How Patients Respond to Drugs

12/27/2005 04:45 PM

Perlegen Sciences, Inc. today announced that Pfizer Inc has made a $50 million equity investment in Perlegen, taking a twelve percent position in the private biotechnology company.

 

Perlegen Sciences and International Rice Research Institute to Collaborate on Rice DNA Variation Study

11/16/2005 08:00 AM

Perlegen Sciences, Inc., and the International Rice Research Institute (IRRI) announced today that they will collaborate to identify DNA variation in fifteen rice strains.

 

Kyushu University and Perlegen Sciences Identify Haplotypes in the Japanese Population

10/26/2005 08:00 AM

Researchers at Kyushu University of Japan, in collaboration with Perlegen Sciences, Inc., have identified common patterns of human DNA sequence variation, or haplotypes, in the Japanese population.

 

International Consortium Completes Map of Human Genetic Variation

10/26/2005 07:00 AM

The International HapMap Consortium today published a comprehensive catalog of human genetic variation, a landmark achievement that is already accelerating the search for genes involved in common d...

 

Wellcome Trust Case Control Consortium Partners with Perlegen and Affymetrix to Search for Genetic Origins of Ten Complex Diseases

10/05/2005 08:00 AM

The Wellcome Trust Case Control Consortium (WTCCC), the Wellcome Trust Sanger Institute (WTSI), Perlegen Sciences and Affymetrix Inc.

 

Perlegen and Merck to Work on High-density, Whole-genome Analysis Linking Genetic Variation to Molecular and Clinical Profiling

10/04/2005 08:00 AM

Perlegen Sciences, Inc. announced today that it will assist Merck & Co., Inc. in conducting a high-density whole genome analysis of more than 1,000 individuals with important clinical characteristics.

 

Research Study Provides First Whole Genome Map of Genetic Variability in Parkinson’s Disease

09/12/2005 08:00 AM

Mayo Clinic researchers in collaboration with scientists at Perlegen Sciences, Inc. and funded by the Michael J. Fox Foundation for Parkinson’s Research have produced the first large-scale whole ge...

 

Perlegen and GlaxoSmithkline Sign New Agreement for Genetic Studies

08/31/2005 08:00 AM

Perlegen Sciences, Inc. announced today that it has expanded its relationship with GlaxoSmithKline with an agreement that enables multiple genetics related studies to be conducted over a period of ...

 

RIKEN and Perlegen Begin Collaboration to Conduct High-Resolution, Whole Genome Studies of up to 47 Common Diseases

07/20/2005 02:30 PM

RIKEN (The Institute of Physical and Chemical Research) and Perlegen Sciences Japan K.K., announced today that they have formed a large-scale, high-throughput research collaboration using Affymetr...

 

Perlegen Sciences and the Pritzker Neuropsychiatric Disorders Research Consortium to Collaborate on Bipolar Disorder Study

07/14/2005 08:00 AM

Perlegen Sciences, Inc. announced today that it is conducting a high density whole genome association study of bipolar disorder (BPD) in collaboration with the Pritzker Neuropsychiatric Disorders R...